Efficacy and safety of a polyherbal formulation in the management of Escherichia coli urinary tract infection.

Q2 Pharmacology, Toxicology and Pharmaceutics

Drug metabolism and personalized therapy Pub Date : 2024-11-11 DOI:10.1515/dmpt-2024-0070

Almas Qureshi, Rais Ur Rahman, Yasmeen Shamsi

{"title":"Efficacy and safety of a polyherbal formulation in the management of Escherichia coli urinary tract infection.","authors":"Almas Qureshi, Rais Ur Rahman, Yasmeen Shamsi","doi":"10.1515/dmpt-2024-0070","DOIUrl":null,"url":null,"abstract":"Objectives: Urinary tract infection (UTI) is one of the most frequent reasons for prescribing antibiotics. Escherichia coli implicated in 75-90 % cases of UTI is becoming increasingly resistant to antibiotics. Finding alternative therapeutic agent for this infection is critical, for which herbal drugs may be an option. In Unani medicine, urinary tract infection (Ṭa'diya Majra-i-Bawl) is treated with herbal drugs possessing Da'fe Ufoonat (antiseptic), Muhallilat (anti-inflammatory) and Mudirrat (diuretic) properties. Polyherbal formulations of such drugs are expected to be beneficial in treating Escherichia coli infection. The aim of the study was to assess the efficacy and safety of a Unani polyherbal formulation aimed to develop a safe and efficacious drug for the treatment of urinary tract infection (Ṭa'diya Majra-i-Bawl) caused by Escherichia coli.Methods: This open-label, single armed clinical study was conducted on patients with clinical signs and symptoms of UTI and positive urine culture for E. coli. Patients were treated with the polyherbal formulation consisting of 50 % hydro-alcoholic extracts of Khar Khasak (Tribulus terrestris), Bhui Amla (Phyllanthus niruri), Kabab Cheeni (Piper cubeba), Beekh -i-Kasni (Cichorium intybus), Beekh-i-Karafs (Apium graveolens), Asl-us-Soos (Glycyrrhiza glabra), and Giloy (Tinospora cordifolia) in a dose of one capsule (500 mg) thrice a day orally with plain water for 42 days.Results: Maximum (83 %) urine cultures turned out negative for E. coli after the completion of therapy.Conclusions: Polyherbal Unani formulation was found to be very effective for the treatment of Urinary tract infection. Clinical and microbiological cure was achieved in maximum number of patients and drug was very well tolerated without any adverse/side effect.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2024-0070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Urinary tract infection (UTI) is one of the most frequent reasons for prescribing antibiotics. Escherichia coli implicated in 75-90 % cases of UTI is becoming increasingly resistant to antibiotics. Finding alternative therapeutic agent for this infection is critical, for which herbal drugs may be an option. In Unani medicine, urinary tract infection (Ṭa'diya Majra-i-Bawl) is treated with herbal drugs possessing Da'fe Ufoonat (antiseptic), Muhallilat (anti-inflammatory) and Mudirrat (diuretic) properties. Polyherbal formulations of such drugs are expected to be beneficial in treating Escherichia coli infection. The aim of the study was to assess the efficacy and safety of a Unani polyherbal formulation aimed to develop a safe and efficacious drug for the treatment of urinary tract infection (Ṭa'diya Majra-i-Bawl) caused by Escherichia coli.

Methods: This open-label, single armed clinical study was conducted on patients with clinical signs and symptoms of UTI and positive urine culture for E. coli. Patients were treated with the polyherbal formulation consisting of 50 % hydro-alcoholic extracts of Khar Khasak (Tribulus terrestris), Bhui Amla (Phyllanthus niruri), Kabab Cheeni (Piper cubeba), Beekh -i-Kasni (Cichorium intybus), Beekh-i-Karafs (Apium graveolens), Asl-us-Soos (Glycyrrhiza glabra), and Giloy (Tinospora cordifolia) in a dose of one capsule (500 mg) thrice a day orally with plain water for 42 days.

Results: Maximum (83 %) urine cultures turned out negative for E. coli after the completion of therapy.

Conclusions: Polyherbal Unani formulation was found to be very effective for the treatment of Urinary tract infection. Clinical and microbiological cure was achieved in maximum number of patients and drug was very well tolerated without any adverse/side effect.

查看原文本刊更多论文

治疗大肠杆菌尿路感染的多草药配方的有效性和安全性。

目的：尿路感染（UTI）是处方抗生素的最常见原因之一。75-90% 的尿路感染病例都与大肠杆菌有关，而且大肠杆菌对抗生素的耐药性越来越强。寻找治疗这种感染的替代药物至关重要，而草药可能是一种选择。在尤那尼医学中，尿路感染（Ṭa'diya Majra-i-Bawl）是用具有 Da'fe Ufoonat（杀菌）、Muhallilat（消炎）和 Mudirrat（利尿）特性的草药治疗的。此类药物的复方草药制剂有望对治疗大肠杆菌感染有益。本研究的目的是评估乌纳尼多草药配方的疗效和安全性，旨在开发一种安全有效的药物，用于治疗由大肠杆菌引起的尿路感染（Ṭa'diya Majra-i-Bawl）：这项开放标签、单药临床研究的对象是有尿路感染临床症状和体征、大肠杆菌尿培养阳性的患者。患者接受了多草药配方的治疗，该配方由 50% 的水醇提取物组成，其中包括 Khar Khasak（刺蒺藜）、Bhui Amla（Phyllanthus niruri）、Kabab Cheeni（Piper cubeba）、Beekh -i-Kasni (Cichorium intybus)、Beekh-i-Karafs (Apium graveolens)、Asl-us-Soos (Glycyrrhiza glabra)和 Giloy (Tinospora cordifolia)，每天三次，每次一粒（500 毫克），用白开水口服，连续 42 天。结果显示治疗结束后，大部分（83%）尿液培养结果显示大肠杆菌呈阴性：结论：多草药乌纳尼配方对治疗尿路感染非常有效。结论：发现多草药乌纳尼配方对治疗尿路感染非常有效，大多数患者都获得了临床和微生物学治愈，而且对药物的耐受性非常好，没有任何不良/副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug metabolism and personalized therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.